Donanemab, a monoclonal antibody targeting amyloid-β (Aβ) plaques, has shown the ability to reduce cerebral amyloid burden in early Alzheimer's disease (AD). However, uncertainties remain regarding its clinical relevance, particularly in relation to tau pathology, APOE ε4 genotype, and methodological limitations in existing trials.
Objective
To conduct a systematic review and exploratory meta-analysis to evaluate the efficacy, safety, and tolerability of donanemab in patients with mild to moderate AD.
Methods
We conducted a systematic review and exploratory meta-analysis following PRISMA guidelines. Randomized controlled trials comparing donanemab to placebo in individuals aged ≥65 years with biomarker-confirmed mild to moderate AD were included. Outcomes included cognitive measures (ADAS-Cog13, MMSE, CDR-SB, iADRS, ADCS-iADL) and adverse events (ARIA-E, ARIA-H, infusion reactions, discontinuations). Random-effects models were used to estimate pooled mean difference (MD) or risk ratio (RR) with 95% confidence intervals. Subgroup analyses were performed by baseline tau burden and APOE ε4 genotype.
Results
Three trials (n = 2054) were included. Donanemab modestly reduced cognitive decline compared to placebo: ADAS-Cog13 (MD, −1.86), CDR-SB (MD, −0.36), MMSE (MD, 0.64), and iADRS (MD, 3.19), with similar effects across tau subgroups. The risk of ARIA-E was markedly increased (RR, 12.39), especially among APOE ε4 homozygotes. Infusion reactions (RR, 11.90) and discontinuations (RR, 3.22) were also more frequent.
Conclusions
Donanemab demonstrated modest cognitive benefits, the clinical significance of which remains uncertain. Independent, longer-term trials with rigorous methodology and active comparators are warranted to more clearly define its therapeutic value in the treatment of AD.
LiXFengXSunX, et al.Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2019. Front Aging Neurosci2022; 14: 937486.
2.
PrinceMAliGCGuerchetM, et al.Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimers Res Ther2016; 8: 23.
3.
McKeownATurnerAAngehrnZ, et al.Health outcome prioritization in Alzheimer's disease: understanding the ethical landscape. J Alzheimers Dis2020; 77: 339–353.
4.
LyketsosCGCarrilloMCRyanJM, et al.Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement2011; 7: 532–539.
5.
SchwarzingerMDufouilC. Forecasting the prevalence of dementia. Lancet Public Health2022; 7: e94–e95.
6.
AisenPSCummingsJDoodyR, et al.The future of anti-amyloid trials. J Prev Alzheimers Dis2020; 7: 146–151.
7.
TatsumiHNakaakiSToriiK, et al.Neuropsychiatric symptoms predict change in quality of life of Alzheimer disease patients: a two-year follow-up study. Psychiatry Clin Neurosci2009; 63: 374–384.
8.
SongCShiJZhangP, et al.Immunotherapy for Alzheimer's disease: targeting beta-amyloid and beyond. Transl Neurodegener2022; 11: 18.
9.
SimsJRZimmerJAEvansCD, et al.Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA2023; 330: 512–527.
10.
LoweSLWillisBAHawdonA, et al.Donanemab (LY3002813) dose-escalation study in Alzheimer's disease. Alzheimers Dement (N Y)2021; 7: e12112.
11.
StoiljkovicMHorvathTLHajosM. Therapy for Alzheimer's disease: missing targets and functional markers?Ageing Res Rev2021; 68: 101318.
12.
BayerTA. Pyroglutamate Abeta cascade as drug target in Alzheimer's disease. Mol Psychiatry2022; 27: 1880–1885.
13.
MintunMALoACDuggan EvansC, et al.Donanemab in early Alzheimer's disease. N Engl J Med2021; 384: 1691–1704.
14.
Hoilund-CarlsenPFAlaviABarrioJR, et al.Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit. Ageing Res Rev2024; 99: 102348.
15.
HampelHElhageAChoM, et al.Amyloid-related imaging abnormalities (ARIA) and their radiological, biological and clinical characteristics: a plain language summary. Neurodegener Dis Manag2024; 14: 51–62.
16.
RabinoviciGDSelkoeDJSchindlerSE, et al.Donanemab: appropriate use recommendations. J Prev Alzheimers Dis2025; 12: 100150.
17.
Serrano-PozoADasSHymanBT. APOE And Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol2021; 20: 68–80.
18.
LiuCCLiuCCKanekiyoT, et al.Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol2013; 9: 106–118.
19.
RaulinACDossSVTrottierZA, et al.Apoe in Alzheimer's disease: pathophysiology and therapeutic strategies. Mol Neurodegener2022; 17: 72.
20.
WangDKowalewskiEKKochG. Application of meta-analysis to evaluate relationships among ARIA-E rate, amyloid reduction rate, and clinical cognitive response in amyloid therapeutic clinical trials for early Alzheimer's disease. Ther Innov Regul Sci2022; 56: 501–516.
21.
GeninEHannequinDWallonD, et al.APOE And Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry2011; 16: 903–907.
22.
BradshawACGeorgesJ. Anti-amyloid therapies for Alzheimer's disease: an Alzheimer Europe position paper and call to action. J Prev Alzheimers Dis2024; 11: 265–273.
23.
TeraoIKodamaW. Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: a systematic review and network meta-analysis. Ageing Res Rev2024; 94: 102203.
24.
KueperJKSpeechleyMMontero-OdassoM. The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): modifications and responsiveness in pre-dementia populations. A narrative review. J Alzheimers Dis2018; 63: 423–444.
25.
O'BryantSEWaringSCCullumCM, et al.Staging dementia using clinical dementia rating scale sum of boxes scores: a Texas Alzheimer's research consortium study. Arch Neurol2008; 65: 1091–1095.
26.
CummingsJApostolovaLRabinoviciGD, et al.Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis2023; 10: 362–377.
27.
RashadARasoolAShaheryarM, et al.Donanemab for Alzheimer's disease: a systematic review of clinical trials. Healthcare (Basel)2022; 11: 32.
28.
PageMJMoherDBossuytPM, et al.PRISMA 2020 Explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. Br Med J2021; 372: n160.
29.
HigginsJPTThomasJChandlerJ, et al.Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition. Chichester, UK: John Wiley & Sons, 2019.
30.
DuboisBVillainNSchneiderL, et al.Alzheimer disease as a clinical-biological construct-an international working group recommendation. JAMA Neurol2024; 81: 1304–1311.
31.
Arevalo-RodriguezISmailagicNRoque-FigulsM, et al.Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev2021; 7: CD010783.
32.
OuzzaniMHammadyHFedorowiczZ, et al.Rayyan-a web and mobile app for systematic reviews. Syst Rev2016; 5: 210.
33.
SterneJACSavovicJPageMJ, et al.Rob 2: a revised tool for assessing risk of bias in randomised trials. Br Med J2019; 366: l4898.
34.
RosenWGMohsRCDavisKL. A new rating scale for Alzheimer's disease. Am J Psychiatry1984; 141: 1356–1364.
35.
FolsteinMFFolsteinSEMcHughPR. Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12: 189–198.
36.
MorrisJC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology1993; 43: 2412–2414.
37.
WesselsAMAndersenSWDowsettSA, et al.The integrated Alzheimer's disease rating scale (iADRS) findings from the EXPEDITION3 trial. J Prev Alzheimers Dis2018; 5: 134–136.
38.
TengELiYManserPT, et al.Cross-sectional and longitudinal assessments of function in prodromal-to-mild Alzheimer's disease: a comparison of the ADCS-ADL and A-IADL-Q scales. Alzheimers Dement (Amst)2023; 15: e12452.
39.
SperlingRAJack, Jr.CRBlackSE, et al.Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement2011; 7: 367–385.
40.
BalduzziSRückerGSchwarzerG. How to perform a meta-analysis with R: a practical tutorial. Evid Based Mental Health2019; 22: 153–160.
41.
DerSimonianRLairdN. Meta-analysis in clinical trials. Control Clin Trials1986; 7: 177–188.
42.
ShamseerLMoherDClarkeM, et al.Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. Br Med J2015; 350: g7647.
43.
BohrmannBBaumannKBenzJ, et al.Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis2012; 28: 49–69.
44.
OstrowitzkiSDeptulaDThurfjellL, et al.Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol2012; 69: 198–207.
45.
SevignyJChiaoPBussiereT, et al.The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature2016; 537: 50–56.
46.
SwansonCJZhangYDhaddaS, et al.A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-abeta protofibril antibody. Alzheimers Res Ther2021; 13: 80.
47.
Hoilund-CarlsenPFWernerTJAlaviA. The unsafe profile of lecanemab. J Alzheimers Dis2025; 105: 62–64.
48.
WesselsAMSiemersERYuP, et al.A combined measure of cognition and function for clinical trials: the Integrated Alzheimer's Disease Rating Scale (iADRS). J Prev Alzheimers Dis2015; 2: 227–241.
49.
WesselsAMBelgerMJohnstonJA, et al.Demonstration of clinical meaningfulness of the Integrated Alzheimer's Disease Rating Scale (iADRS): association between change in iadrs scores and patient and caregiver health outcomes. J Alzheimers Dis2022; 88: 577–588.
50.
TolarMAbushakraSHeyJA, et al.Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval. Alzheimers Res Ther2020; 12: 95.
51.
SurCKostJScottD, et al.BACE Inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain. Brain2020; 143: 3816–3826.
52.
ZimmerJAShcherbininSDevous, SrMD, et al.Lanabecestat: neuroimaging results in early symptomatic Alzheimer's disease. Alzheimers Dement (N Y)2021; 7: e12123.
53.
NovakGFoxNCleggS, et al.Changes in brain volume with bapineuzumab in mild to moderate Alzheimer's disease. J Alzheimers Dis2016; 49: 1123–1134.
54.
AlvesFKalinowskiPAytonS. Accelerated brain volume loss caused by anti-beta-amyloid drugs: a systematic review and meta-analysis. Neurology2023; 100: e2114–e2124.
55.
LenzerJBrownleeS. Donanemab: conflicts of interest found in FDA committee that approved new Alzheimer's drug. Br Med J2024; 386: q2010.
56.
Hoilund-CarlsenPFRevheimMEAlaviA, et al.Amyloid PET: a questionable single primary surrogate efficacy measure on Alzheimer immunotherapy trials. J Alzheimers Dis2022; 90: 1395–1399.
57.
Hoilund-CarlsenPFAlaviACastellaniRJ, et al.Alzheimer's amyloid hypothesis and antibody therapy: melting glaciers?Int J Mol Sci2024; 25: 20240331.
58.
US Food and Drug Administration. Peripheral and central nervous system drugs advisory committee meeting briefing document: Donanemab for Alzheimer’s Disease, https://www.fda.gov (2023, accessed 15 May 2025).
59.
KnopmanDSJonesDTGreiciusMD. Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement2021; 17: 696–701.
60.
AndrewsJSDesaiUKirsonNY, et al.Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials. Alzheimers Dement (N Y)2019; 5: 354–363.
61.
XuHGarcia-PtacekSJonssonL, et al.Long-term effects of cholinesterase inhibitors on cognitive decline and mortality. Neurology2021; 96: e2220–e2230.
62.
XuHHabichAFerreiraD, et al.Long-term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: an up to 10-year follow-up study. Alzheimers Dement2024; 20: 6740–6754.
63.
VeronikiAAAshoorHMRiosP, et al.Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis. BMJ Open2022; 12: e053012.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
